

Alejandro Gutierrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2514311/publications.pdf>

Version: 2024-02-01

72
papers

6,331
citations

109264

35
h-index

128225

60
g-index

74
all docs

74
docs citations

74
times ranked

11120
citing authors

#	ARTICLE	IF	CITATIONS
1	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	3.3	6
2	Supramolecular assembly of GSK3 β as a cellular response to amino acid starvation. <i>Molecular Cell</i> , 2022, 82, 2858-2870.e8.	4.5	3
3	SOD2 Promotes Acute Leukemia Adaptation to Amino Acid Starvation Through the N-Degron Pathway. <i>Klinische Padiatrie</i> , 2022, , .	0.2	0
4	PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. <i>Leukemia</i> , 2021, 35, 679-690.	3.3	11
5	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05 β 001 and 11 β 001. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	0.8	26
6	METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. <i>Molecular Cell</i> , 2021, 81, 3323-3338.e14.	4.5	153
7	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. <i>Cancer Discovery</i> , 2020, 10, 1690-1705.	7.7	38
8	Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	12
9	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2019, 14, e0221288.	1.1	16
10	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Cancer Cell</i> , 2019, 35, 664-676.e7.	7.7	70
11	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. , 2019, 231, .		1
12	Inducible Phase Separation of GSK3 β As a Mechanism for Asparaginase Resistance in Acute Leukemias. <i>Blood</i> , 2019, 134, 169-169.	0.6	0
13	An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018, 32, 1970-1983.	3.3	282
14	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2126-2137.	3.3	48
15	Acute myeloid/T-cell lymphoblastic leukaemia (<scp>AMTL</scp>): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. <i>British Journal of Haematology</i> , 2018, 180, 919-924.	1.2	29
16	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	4.2	37
17	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	4.2	22
18	Pathobiology of Acute Lymphoblastic Leukemia. , 2018, , 1005-1019.e11.		1

#	ARTICLE	IF	CITATIONS
19	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , 2018, 132, 889-889.	0.6	0
20	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2017, 7, 1336-1353.	7.7	48
21	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. <i>Genes and Development</i> , 2017, 31, 1456-1468.	2.7	41
22	An Off-the-Shelf, α Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies. <i>Blood</i> , 2017, 130, 844-844.	0.6	2
23	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227
24	Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 335-369.	0.8	19
25	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	0.6	1
26	An X-linked tumor suppressor in T-ALL. <i>Blood</i> , 2015, 125, 3-4.	0.6	4
27	A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1395-1402.	0.8	34
28	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the β -secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000539.	0.5	47
29	Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1819-1827.	3.3	49
30	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. <i>Blood</i> , 2014, 123, 1040-1050.	0.6	129
31	Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. <i>Haematologica</i> , 2014, 99, 94-102.	1.7	84
32	Loss of function <i>tp53</i> mutations do not accelerate the onset of <i>myc</i> -induced T-cell acute lymphoblastic leukaemia in the zebrafish. <i>British Journal of Haematology</i> , 2014, 166, 84-90.	1.2	16
33	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 364-370.	9.4	333
34	Cyclin C is a haploinsufficient tumour suppressor. <i>Nature Cell Biology</i> , 2014, 16, 1080-1091.	4.6	124
35	Thymocyte transformation enhanced. <i>Nature Medicine</i> , 2014, 20, 1096-1097.	15.2	1
36	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	6.0	665

#	ARTICLE	IF	CITATIONS
37	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	7.7	201
38	Leukemia Propagating Cells Akt Up. <i>Cancer Cell</i> , 2014, 25, 263-265.	7.7	2
39	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 644-655.	3.9	180
40	Abstract PR02: Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL. , 2014, , .		0
41	Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. , 2014, , .		0
42	TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2013, 3, 564-577.	7.7	122
43	The TAL1 complex targets the <i>FBXW7</i> tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2013, 210, 1545-1557.	4.2	107
44	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. <i>Blood</i> , 2012, 120, 3764-3773.	0.6	132
45	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 209-221.	7.7	262
46	NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. <i>PLoS ONE</i> , 2012, 7, e39725.	1.1	31
47	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. <i>Blood</i> , 2012, 120, 3558-3558.	0.6	2
48	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1470-1470.	0.6	1
49	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	0.6	162
50	Shared acquired genomic changes in zebrafish and human T-ALL. <i>Oncogene</i> , 2011, 30, 4289-4296.	2.6	42
51	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. <i>Nature</i> , 2011, 471, 104-109.	13.7	558
52	Aberrant AKT activation drives well-differentiated liposarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16386-16391.	3.3	50
53	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 1595-1603.	4.2	104
54	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Cell Biology</i> , 2011, 194, i4-i4.	2.3	1

#	ARTICLE	IF	CITATIONS
55	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. American Journal of Hematology, 2010, 85, 135-137.	2.0	3
56	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood, 2010, 115, 2845-2851.	0.6	112
57	Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood, 2010, 115, 1735-1745.	0.6	61
58	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	7.7	141
59	Liquid chromatography-mass spectrometry (LC-MS) of steroid hormone metabolites and its applications. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 546-555.	1.2	78
60	Absence of Biallelic γ TCR Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	0.8	93
61	Molecular Targeted Therapies in T-Cell Acute Lymphoblastic Leukemia. , 2010, , 19-30.		1
62	Cell and molecular biology of human leukaemias. , 2010, , 4214-4221.		0
63	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 647-650.	0.6	414
64	Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. Molecular and Cellular Biology, 2009, 29, 5911-5922.	1.1	33
65	Pten Inactivating Mutations Promote Loss of MYC -Oncogene Addiction- in a Conditional Zebrafish Model of T-ALL. Blood, 2009, 114, 3977-3977.	0.6	0
66	Alu elements mediate MYB gene tandem duplication in human T-ALL. Journal of Experimental Medicine, 2007, 204, 3059-3066.	4.2	85
67	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature, 2007, 447, 966-971.	13.7	355
68	Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. British Journal of Haematology, 2007, 138, 169-175.	1.2	115
69	NOTCH and PI3K-AKT Pathways Intertwined. Cancer Cell, 2007, 12, 411-413.	7.7	106
70	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukemias. Blood, 2006, 108, 1405-1405.	0.6	0
71	Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL. Blood, 2006, 108, 1408-1408.	0.6	0
72	Liquid Chromatography/Electron Capture Atmospheric Pressure Chemical Ionization/Mass Spectrometry: Analysis of Pentafluorobenzyl Derivatives of Biomolecules and Drugs in the Attomole Range. Analytical Chemistry, 2000, 72, 3007-3013.	3.2	197